Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Novartis reports positive data in Cosentyx study

Novartis announced positive new data from a Phase III trial evaluating the efficacy and safety of Cosentyx (secukinumab) in non-radiographic axial spondyloarthritis.

Read More »

FDA Approves GSK’s Nucala for Children with Severe Eosinophilic Asthma

The FDA greenlit GlaxoSmithKline’s Nucala (mepolizumab) for treating severe eosinophilic asthma in children as young as 6 years.

Read More »

GSK to Acquire Celiac-Focused Sitari Pharmaceuticals

GlaxoSmithKline will acquire San Diego-based Sitari Pharmaceuticals and the company’s transglutaminase 2 small molecule program for celiac disease.

Read More »

New Data Presented at ECTRIMS Reinforce Long-term Benefits of Tecfidera Over 10 Years

Biogen Inc. announced new data to support the consistent, long-term benefits of treatment with Tecfidera (dimethyl fumarate) over 10 years, as well as additional diroximel fumarate data that further characterize the tolerability profile of this investigational oral fumarate for relapsing multiple sclerosis.

Read More »

Amgen drug shrinks lung cancer tumors in half of patients: study

An experimental Amgen Inc. drug that targets a specific genetic mutation reduced tumor size in around half of advanced lung cancer patients given the highest dose in a small, early-stage trial.

Read More »

Ardelyx’s Tenapanor Hits the Mark in CKD Trial

Ardelyx’s Phase III AMPLIFY study of tenapanor achieved the clinical trial’s primary endpoint, as well as all key secondary endpoints, in treating patients with chronic kidney disease (CKD).

Read More »

AstraZeneca Reports Positive Results in Late-Stage Trials for Brilinta, Farxiga

AstraZeneca reported positive results from clinical trial programs for Brilinta and Farxiga, causing stock to jump 3.4 percent.

Read More »

Genentech’s Xofluza Reduces Flu Threat by 86 Percent Following Exposure, Data Shows

In a late-stage study, Genentech’s flu drug Xofluza showed significant efficacy as a preventative treatment.

Read More »

Roche test showed Tecentriq helped vs bladder cancer

Roche Holding’s Tecentriq drug combined with platinum-based chemotherapy reduced the risk of the disease worsening or death in patients with advanced bladder cancer.

Read More »

Merck’s Keytruda Approved for Esophageal Cancer

The U.S. Food and Drug Administration approved the anti-PD-1 therapy Keytruda as a monotherapy for patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 with disease progression after one or more previous lines of systemic therapy.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom